EARNEST Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

EARNEST Partners’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-61	Closed	-$10.8K	–	324
2023 Q3	$10.8K	Hold	61	–	–	﹤0.01%	618
2023 Q2	$11.6K	Hold	61	–	–	﹤0.01%	599
2023 Q1	$12.2K	Hold	61	–	–	﹤0.01%	582
2022 Q4	$14.5K	Hold	61	–	–	﹤0.01%	539
2022 Q3	$12K	Hold	61	–	–	﹤0.01%	544
2022 Q2	$9K	Hold	61	–	–	﹤0.01%	613
2022 Q1	$10K	Hold	61	–	–	﹤0.01%	635
2021 Q4	$10K	Hold	61	–	–	﹤0.01%	664
2021 Q3	$12K	Hold	61	–	–	﹤0.01%	593
2021 Q2	$10K	Hold	61	–	–	﹤0.01%	645
2021 Q1	$9K	Hold	61	–	–	﹤0.01%	654
2020 Q4	$8K	Hold	61	–	–	﹤0.01%	665
2020 Q3	$9K	Hold	61	–	–	﹤0.01%	581
2020 Q2	$9K	Buy	61 +34	+126%	+$4.58K	﹤0.01%	580
2020 Q1	$3K	Hold	27	–	–	﹤0.01%	774
2019 Q4	$3K	Hold	27	–	–	﹤0.01%	897
2019 Q3	$2K	Hold	27	–	–	﹤0.01%	956
2019 Q2	$2K	Hold	27	–	–	﹤0.01%	971
2019 Q1	$3K	Hold	27	–	–	﹤0.01%	888
2018 Q4	$2K	Hold	27	–	–	﹤0.01%	938
2018 Q3	$2K	Hold	27	–	–	﹤0.01%	991
2018 Q2	$3K	Hold	27	–	–	﹤0.01%	905
2018 Q1	$3K	Hold	27	–	–	﹤0.01%	878
2017 Q4	$3K	Buy	+27	New	+$3.39K	﹤0.01%	880
2017 Q1	–	Sell	-27	Closed	-$1K	–	265
2016 Q4	$1K	Buy	+27	New	+$1.13K	﹤0.01%	1010

Other funds holding ALNY

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

EARNEST Partners's ALNY Position: Q4 2023 in Review

EARNEST Partners sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2023, closing a stake of 61 shares — an estimated $10.8K sold.

EARNEST Partners first reported a position in ALNY in Q4 2016 and held it in 25 quarters. The position peaked at $14.5K in Q4 2022. 499 funds tracked by Wall St. Rank hold ALNY as of Q4 2023.

EARNEST Partners reported no remaining Alnylam Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
EARNEST Partners sold 61 Alnylam Pharmaceuticals shares in Q4 2023, an estimated $10.8K.
EARNEST Partners first reported a position in Alnylam Pharmaceuticals in Q4 2016 and held it in 25 quarters.
EARNEST Partners's Alnylam Pharmaceuticals position peaked at $14.5K in Q4 2022.
499 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2023.

Based on EARNEST Partners's 13F filing for Q4 2023, filed 14 Feb 2024.